Full-Time

Research Technician

In Vivo Husbandry

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Compensation Overview

$45k - $53k/yr

Entry, Junior

Madison, WI, USA

In Person

Category
Lab & Research
Life Sciences
Requirements
  • High school diploma
  • Some previous demonstrated experience working with rodents in a research laboratory setting
  • Background in animal husbandry, restraint and handling
  • Must demonstrate a commitment to quality care of laboratory animals
  • Must possess a strong attention to detail
  • Ability to read, record and communicate information
  • Position encounters animal waste (bedding, dust, and shavings) and odors (animal smell) up to 50% of shift
  • Able to use and manipulate tools and equipment, including but not limited to: Cage washer, scales, bedding dump station, bedding dispenser, animal transfer station, ID applicators, cleaning equipment
Responsibilities
  • Performs routine animal handling and restraint
  • Perform routine cage changes
  • Perform animal health checks
  • Perform general husbandry duties
  • Sanitize animal holding rooms and equipment
  • May email researchers with study-specific updates
  • Euthanizes animals as needed following standard operating procedures
  • Follows all safety procedures including special precautions for working in ABSL2/+ rooms
  • Other duties as assigned
  • Records ear tags and updates animal census
  • Maintains animal holding room Daily Room Activity logs
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing the genes responsible for them. The company uses RNA interference (RNAi), a natural process that reduces the expression of specific genes, to achieve effective treatment outcomes. This method allows for significant and lasting reductions in the activity of harmful genes, which can help manage or potentially reverse diseases like cystic fibrosis and hepatitis B. Arrowhead stands out from its competitors by focusing specifically on RNAi-based therapies and leveraging a wide range of RNA chemistries and delivery methods. The company aims to meet unmet medical needs by providing new treatment options for conditions that currently lack effective therapies, generating revenue through partnerships, licensing agreements, and future sales of approved therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's collaboration with Sarepta includes a $500M upfront payment for RNA drug development.
  • Positive Phase 2 data for plozasiran boosts Arrowhead's credibility in treating hypertriglyceridemia.
  • Strategic financing with Sixth Street provides capital to advance Arrowhead's research pipeline.

What critics are saying

  • Increased competition from companies like Alnylam may impact Arrowhead's market share.
  • Potential regulatory scrutiny could delay Arrowhead's clinical trials for RNAi therapies.
  • Reliance on strategic financing may lead to increased debt obligations for Arrowhead.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead uses RNAi to target and silence disease-causing genes effectively.
  • The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
  • Arrowhead's strategic partnerships enhance its capabilities in developing innovative RNAi therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

BioSpace
Apr 15th, 2025
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.

PharmaData
Mar 1st, 2025
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.

Business Wire
Feb 28th, 2025
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides

World Pharmaceuticals
Nov 29th, 2024
Dev4All and Pharmaseed enter commercial partnership for preclinical R&D

Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.

BioSpace
Nov 26th, 2024
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.